Skip to main
RZLT

Rezolute (RZLT) Stock Forecast & Price Target

Rezolute (RZLT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Rezolute Inc. has demonstrated promising advancements in its clinical pipeline, particularly with ersodetug showing a 25% reduction in hypoglycemia time in patients, while the Phase 2b RIZE study indicated a remarkable 70-90% reduction in weekly hypoglycemia events. The company's strategic engagement in research and collaboration with medical communities supports its focus on addressing unmet medical needs for rare endocrine disorders, specifically congenital hyperinsulinism. Positive patient outcomes observed in studies, along with a favorable safety profile for its lead candidate, bolster Rezolute's potential for successful product development and regulatory approvals, underpinning a positive outlook for the company's financial performance.

Bears say

Rezolute Inc is currently facing significant challenges following the failure of its drug candidate, Ersodetug, to demonstrate statistically significant efficacy compared to placebo, raising concerns about the viability of its product pipeline. The inconsistent results in clinical trials, particularly in the Ph3 study where treatment effects collapsed and the placebo response increased unexpectedly, contribute to a negative sentiment around the company's ability to successfully advance its therapies for rare diseases. Furthermore, Rezolute's reliance on successful product development and regulatory approvals exposes it to inherent risks, including potential regulatory hurdles and market complexities, which could impede financial performance and growth prospects in the near term.

Rezolute (RZLT) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rezolute (RZLT) Forecast

Analysts have given Rezolute (RZLT) a Buy based on their latest research and market trends.

According to 7 analysts, Rezolute (RZLT) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rezolute (RZLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.